Objective: To observe the anti-hepatitis B virus (HBV) efficacy and the action mechanism of HH capsule. Method: Dalian Elite ODS-BP C18 column was used to study the HH capsule HPLC fingerprint. HBV transgenic mice were randomly divided into four groups

such as matrine group

high and low dose HH capsule groups

and model group. The mice in matrine group received the same volume of suspension containing 150 mg·kg-1·d-1 matrine; mice in high and low dose HH capsule groups received the same volume of suspension containing 7 g·kg-1·d-1 and 2 g·kg-1·d-1HH capsule; the mice in model group received the same volume of normal saline. After treatment for five weeks

ELISA method was used to detect hepatitis B virus surface antigen (HBsAg)

IFNα and IFNβ in the serum as well as HBsAg in liver tissues. Conventional HE staining was used to observe pathological changes in liver tissues

and quantitative PCR was used to detect hepatitis B virus DNA (HBVDNA) in serum and liver tissues. Result: The 14 characteristic peaks were identified in HH capsules fingerprint

including the 1st peak of gallic acid

the 8th peak of corilagin

the 9th peak of polydatin

the 10th peak of ellagic acid

the 13th peak of glycyrrhizin

and the 14th peak of oleanolic acid. As compared with the model group

high dose (7 g·kg-1·d-1) HH capsule can significantly reduce HBsAg and HBVDNA levels in the serum and liver of HBV transgenic mice

with statistically significant difference(P<0.01)

but the difference was not statistically significant as compared with matrine group. High-dose HH capsule could significantly increase the levels of IFN-α and IFN-β in the mice with statistically significant difference(P<0.01

P<0.05). Conclusion: HH capsule has reliable anti-HBV effect

which may be associated with increasing IFN-α and IFN-β levels.